1. Scrip
  2. >>Business

Spotlight On Israel: Compugen Comes Forth

 
• By Lucie Ellis-Taitt

Compugen, a predictive drug discovery and development company, plays an important role within Israel's biopharma sector as one of the oldest businesses in an immature market. Building on its 25-year history, the company is about to embark on a new challenge: clinical development.

Compugen Quote
Compugen offices in Holon, Israel • Source: Lucie Ellis

Compugen Ltd. is an example of success for Israel's emerging biopharma industry. The company's long journey to clinical drug development spans many years and covers several evolutionary steps, from a computational service provider to early-stage research leader and critical employer for the Israeli biopharma sector.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

In Brief: Merck To Invest $1bn In New US Biologics Production

 
• By Sushmita Panda

Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.